These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Association between the XRCC1 Arg399Gln polymorphism and head and neck cancer susceptibility: a meta-analysis based on case-control studies.
    Author: Liu C, Yin Q, Jiao G, Zhou X, Ying M, Gao W, Hu J, Wei L, Wang N, Wang Y.
    Journal: DNA Cell Biol; 2014 Jun; 33(6):378-87. PubMed ID: 24694255.
    Abstract:
    Published data regarding the association between the XRCC1 Arg399Gln polymorphism and head and neck cancer (HNC) susceptibility showed inconsistent results. This meta-analysis of eligible literatures was performed to draw a more precise estimation of the relationship. We systematically searched PubMed, Embase, and Web of Science with a time limit of Oct 28, 2013. Summary odds ratios (ORs) with 95% CIs were used to assess the strength of association between XRCC1 Arg399Gln polymorphism and HNC susceptibility using random-effect model. A total of 27 case-control studies including 5942 cases and 9041 controls were included for analysis. Meta-analysis of total studies showed that the XRCC1 Arg399Gln variant carriers were not susceptible to HNC (AA vs. GG: OR=0.92, 95% CI=0.77-1.11; AG vs. GG: OR=1.05, 95% CI=0.76-1.44; the dominant model AA+AG vs. GG: OR=1.00, 95% CI=0.78-1.29; the recessive model AA vs. AG+GG: OR=0.91, 95% CI=0.71-1.16). Further, subgroup analyses by ethnicity and source of controls did not identify any significant associations of XRCC1 Arg399Gln polymorphism with head and neck susceptibility in any populations. Our meta-analysis suggested that the XRCC1 Arg399Gln polymorphism was not a risk factor for HNC susceptibility.
    [Abstract] [Full Text] [Related] [New Search]